Susquehanna International Group, LLP Blueprint Medicines Corp Call Options Transaction History

Susquehanna International Group, LLP

$560 Billion
Q3 2024

Call Options

28 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	SELL	$84.1 - $120.5 $4.15 Million - $5.94 Million	-49,300 Reduced 23.25%	162,700 $15 Million
Q2 2024 Aug 15, 2024	BUY	$85.18 - $108.78 $4.36 Million - $5.57 Million	51,200 Added 31.84%	212,000 $22.8 Million
Q1 2024 May 07, 2024	BUY	$73.17 - $99.79 $4.69 Million - $6.4 Million	64,100 Added 66.29%	160,800 $15.3 Million
Q4 2023 Feb 14, 2024	BUY	$43.96 - $92.84 $2.29 Million - $4.83 Million	52,000 Added 116.33%	96,700 $8.92 Million
Q3 2023 Nov 14, 2023	SELL	$46.9 - $66.0 $1.03 Million - $1.45 Million	-21,900 Reduced 32.88%	44,700 $2.24 Million
Q2 2023 Aug 11, 2023	SELL	$42.2 - $66.37 $1.06 Million - $1.67 Million	-25,200 Reduced 27.45%	66,600 $4.21 Million
Q1 2023 May 16, 2023	BUY	$37.97 - $50.0 $1.8 Million - $2.37 Million	47,300 Added 106.29%	91,800 $4.13 Million
Q4 2022 Feb 14, 2023	SELL	$41.06 - $66.48 $3.29 Million - $5.33 Million	-80,200 Reduced 64.31%	44,500 $1.95 Million
Q3 2022 Nov 14, 2022	BUY	$49.93 - $77.7 $1.02 Million - $1.59 Million	20,400 Added 19.56%	124,700 $8.22 Million
Q2 2022 Aug 15, 2022	BUY	$45.23 - $70.15 $2.48 Million - $3.85 Million	54,900 Added 111.13%	104,300 $5.27 Million
Q1 2022 May 16, 2022	BUY	$54.1 - $110.08 $1.38 Million - $2.81 Million	25,500 Added 106.69%	49,400 $3.16 Million
Q4 2021 Feb 14, 2022	SELL	$94.25 - $115.99 $1.16 Million - $1.43 Million	-12,300 Reduced 33.98%	23,900 $2.56 Million
Q2 2021 Aug 11, 2021	BUY	$82.78 - $101.0 $91,058 - $111,100	1,100 Added 3.13%	36,200 $3.18 Million
Q1 2021 May 17, 2021	BUY	$90.71 - $108.28 $925,241 - $1.1 Million	10,200 Added 40.96%	35,100 $3.41 Million
Q4 2020 Feb 16, 2021	SELL	$92.08 - $124.48 $7.36 Million - $9.95 Million	-79,900 Reduced 76.24%	24,900 $2.79 Million
Q3 2020 Nov 16, 2020	BUY	$66.45 - $92.7 $1.67 Million - $2.34 Million	25,200 Added 31.66%	104,800 $9.72 Million
Q2 2020 Aug 14, 2020	SELL	$57.09 - $79.27 $673,662 - $935,386	-11,800 Reduced 12.91%	79,600 $6.21 Million
Q1 2020 May 15, 2020	BUY	$48.11 - $82.22 $697,595 - $1.19 Million	14,500 Added 18.86%	91,400 $5.35 Million
Q4 2019 Feb 14, 2020	SELL	$66.73 - $82.59 $30.1 Million - $37.3 Million	-451,700 Reduced 85.45%	76,900 $6.16 Million
Q3 2019 Nov 14, 2019	BUY	$72.9 - $101.41 $12.3 Million - $17.1 Million	169,100 Added 47.04%	528,600 $38.8 Million
Q2 2019 Aug 14, 2019	BUY	$73.54 - $97.8 $21.3 Million - $28.4 Million	290,200 Added 418.76%	359,500 $33.9 Million
Q1 2019 May 15, 2019	BUY	$48.7 - $86.6 $194,800 - $346,400	4,000 Added 6.13%	69,300 $5.55 Million
Q4 2018 Feb 14, 2019	BUY	$45.57 - $74.26 $997,983 - $1.63 Million	21,900 Added 50.46%	65,300 $3.52 Million
Q3 2018 Nov 14, 2018	SELL	$58.91 - $78.32 $4.56 Million - $6.06 Million	-77,400 Reduced 64.07%	43,400 $3.39 Million
Q2 2018 Aug 14, 2018	BUY	$60.96 - $101.18 $4.61 Million - $7.65 Million	75,600 Added 167.26%	120,800 $7.67 Million
Q1 2018 May 15, 2018	SELL	$73.28 - $102.95 $8.73 Million - $12.3 Million	-119,100 Reduced 72.49%	45,200 $4.15 Million
Q4 2017 Feb 14, 2018	BUY	$62.91 - $88.32 $9.08 Million - $12.8 Million	144,400 Added 725.63%	164,300 $12.4 Million
Q3 2017 Nov 14, 2017	BUY	$42.37 - $69.67 $843,163 - $1.39 Million	19,900	19,900 $1.39 Million

Others Institutions Holding BPMC

# of Institutions

350

Shares Held

60.3M

Call Options Held

2.25M

Put Options Held

1.18M

Vanguard Group Inc Valley Forge, PA

6.68M
Shares

$593 Million
0.01% of portfolio
Black Rock Inc. New York, NY

6.65M
Shares

$590 Million
0.02% of portfolio
Price T Rowe Associates Inc Baltimore, MD

5.39M
Shares

$478 Million
0.06% of portfolio
Wellington Management Group LLP Boston, MA

3.96M
Shares

$352 Million
0.07% of portfolio
State Street Corp Boston, MA

2.77M
Shares

$245 Million
0.01% of portfolio

View Full List

About Blueprint Medicines Corp

Ticker BPMC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,719,600
Market Cap $5.3B
Description
Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibit...

More about BPMC

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

News

Stay updated on Susquehanna International Group, LLP with notifications on news.

Account